Patents by Inventor Alan L. Schneyer
Alan L. Schneyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170183411Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: ApplicationFiled: December 12, 2016Publication date: June 29, 2017Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Patent number: 9556251Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: GrantFiled: July 16, 2014Date of Patent: January 31, 2017Assignee: THE GENERAL HOSPITAL CORPORATIONInventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Publication number: 20150072927Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: ApplicationFiled: July 16, 2014Publication date: March 12, 2015Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Patent number: 8865168Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: GrantFiled: October 18, 2012Date of Patent: October 21, 2014Assignee: The General Hospital CorporationInventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Patent number: 8637023Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: GrantFiled: February 28, 2012Date of Patent: January 28, 2014Assignee: The General Hospital CorporationInventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
USE OF MODULATORS OF COMPOUNDS OF TGF-BETA SUPERFAMILY TO REGULATE HEPCIDIN-MEDIATED IRON METABOLISM
Publication number: 20130149304Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: ApplicationFiled: October 18, 2012Publication date: June 13, 2013Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf -
Patent number: 8293236Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: GrantFiled: June 28, 2011Date of Patent: October 23, 2012Assignee: The General Hospital CorporationInventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Publication number: 20120258105Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: ApplicationFiled: February 28, 2012Publication date: October 11, 2012Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Publication number: 20120064076Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: ApplicationFiled: June 28, 2011Publication date: March 15, 2012Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Patent number: 7968091Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: GrantFiled: February 16, 2006Date of Patent: June 28, 2011Assignee: The General Hospital CorporationInventors: Clifford J. Woolf, Tarek A. Samad, Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Alan L. Schneyer
-
Publication number: 20080260736Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: ApplicationFiled: February 16, 2006Publication date: October 23, 2008Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Patent number: 5824637Abstract: A method for contraception which features administering to a patient a contraceptive agent having activin-antagonist activity. The contraceptive agent results in inhibition of the activin-stimulated release of FSH, thereby resulting in a decrease in fertility and facilitating contraception in the patient.Type: GrantFiled: February 28, 1997Date of Patent: October 20, 1998Assignee: The General Hospital CorporationInventors: William F. Crowley, J. Larry Jameson, Alan L. Schneyer, Jeffrey Weiss
-
Patent number: 5658876Abstract: A method for contraception which features administering to a patient a contraceptive agent having activin-antagonist activity. The contraceptive agent results in inhibition of the activin-stimulated release of FSH, thereby resulting in a decrease in fertility and facilitating contraception in the patient.Type: GrantFiled: April 28, 1994Date of Patent: August 19, 1997Assignee: The General Hospital CorporationInventors: William F. Crowley, J. Larry Jameson, Alan L. Schneyer, Jeffrey Weiss
-
Patent number: 4921808Abstract: The present disclosure relates to an improved method based on hormone-receptor binding for the determination of follicle stimulating hormone and to improved reagents useful for the determination of follicle stimulating hormone in a hormone-receptor binding assay.Type: GrantFiled: June 25, 1986Date of Patent: May 1, 1990Assignee: The Albany Medical College of Union UniversityInventors: Alan L. Schneyer, Patrick M. Sluss, Bosukonda Dattatreyamurty, Leo E. Reichert, Jr.
